Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS9531 vs Semaglutide in Obesity
NCT07285902Phase 3Active, not recruiting
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Mar 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS9531 in obesity, sponsored by Fujian Shengdi Pharmaceuticals. Started Dec 2025; status: active, not recruiting.
02
Drugs
HRS9531
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07285902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285902.